Blood and Genes in Acute Coronary Syndrome

• Research type

  Research Study

• Full title

  Blood and Genes in Acute Coronary Syndrome (The BG-ACS Study)

• IRAS ID

  159833

• Contact name

  Willem Ouwehand

• Contact email

  who1000@cam.ac.uk

• Sponsor organisation

  Papworth Hospital NHS Foundation Trust & University of Cambridge

• Duration of Study in the UK

  2 years, 11 months, 31 days

• Research summary

  This study aims to investigate genetic predisposition and biochemical processes involved in acute coronary syndrome. Patients presenting at Papworth hospital will be invited to participate. Participation in the study will involve one blood sample at approximately 24-36 hours (+/- 12 hours) after admission. Optional additional biomaterial such as bone marrow or blood clots may be collected as part of the study if they are collected as part of a routine care procedure and superfluous to any diagnostic procedures and would be discarded.

  Various genetic and biochemical measurements will be performed using the collected blood sample, including sequencing of genetic material such as DNA and RNA. Analysis results will be compared to controls recruited under separate ethics (Genetic analysis of platelets in healthy individuals, REC reference 10/H0304/65). Overlap of the findings will also be assessed with a stroke study using similar methodology to elucidate possible shared risk factors (Genes and Platelets in Stroke - Glycoprotein Six in Stroke (The GYPSIE study) - REC reference 14/EE/1062).

  We will be recruiting 500 with acute coronary syndrome.

  We will collect Biological Materials for use in research that aims:
  1) To investigate the genetic basis of cardiac events, particularly Acute Coronary Syndrome
  2) To investigate biomarkers in the blood and their connection to cardiac events
  3) To unravel the molecular mechanism by which the DNA variants affect platelet function, and more generally result in cardiac events

  The potential benefits of the research for the NHS and the wider public are:
  - Improved diagnosis (within 5 years) for cases with cardiac events, particularly acute coronary syndrome
  - Possible identification of new drug targets for patients with cardiac events, particularly acute coronary syndrome
  -Better classification of cardiac events into subgroups benefiting from different treatments

• REC name

  East of England - Cambridge Central Research Ethics Committee

• REC reference

  15/EE/0320

• Date of REC Opinion

  17 Nov 2015

• REC opinion

  Further Information Favourable Opinion